Key result
Angiotensin 1-7 reverses glucose-induced β-cell dedifferentiation and improves insulin secretion via the Wnt/β-catenin/FoxO1 pathway.
Why the study?
The mechanisms by which angiotensin (1-7) attenuates high glucose-induced islet beta-cell dedifferentiation remained unelucidated, including whether effects are mediated via the Wnt/beta-catenin/FoxO1 pathway.
Does Angiotensin (1-7) reverse high glucose-induced islet β cell dedifferentiation in vitro?
Does Angiotensin (1-7) reverse high glucose-induced islet β cell dedifferentiation in vitro?
Angiotensin (1-7) reverses high glucose-induced pancreatic β cell dedifferentiation via the Wnt/β-catenin/FoxO1 pathway, suggesting a potential therapeutic mechanism for diabetes.
May support β-cell protection research in diabetes; leaves open translation from animal models to clinical use.
INTRODUCTION: Recent studies have shown that a decline in isletβ cells quality is due to β-cell dedifferentiation, not only β-cell apoptosis. Angiotensin (1-7) [Ang(1-7)] could attenuate high glucose-induced apoptosis and dedifferentiation of pancreaticβ cells by combining with MAS receptors. However, the mechanism of such action has not been elucidated. Recent studies have revealed that Wnt/β-catenin and forkhead box transcription factor O1 (FoxO1) are associated with β-cell dedifferentiation. Our study aims to explore whether the effects of Ang(1-7)on islet b cell dedifferentiation are mediated through the Wnt/β-catenin/FoxO1 pathway. MATERIAL AND METHODS: Isletβ cells were divided into 6 groups: a control group, a high-glucose group, high glucose with Ang(1-7) group, high-glucose with Ang(1-7) and A779 group, high-glucose with angiotensin(1-7) and CHIR99021 group, and high-glucose with CHIR99021 group. A779 is a kind of MAS receptor antagonist that blocks the action of Ang(1-7), and CHIR99021 is a Wnt pathway activator. The morphology of pancreaticβ cells was observed in each group after 48 hours of intervention. β-cell insulin secretory function and expressions of relevant factors were measured. RESULTS: Compared with the control group, the cell morphology became degraded in the high-glucose group and the capability of insulin secretion was reduced. Meanwhile, the expressions of matureβ cells markers [pancreatic and duodenal homeobox 1 (Pdx1) and MAF BZIP transcription factor A (MafA)] were reduced, while the expressions of endocrine progenitor cells makers [octamer-binding transcription factor 4 (Oct4) and Nanog] were increased. The addition of CHIR99021 resulted in profound deep destruction ofβ cells compared with the high-glucose group. However, such changes were dramatically reversed following the treatment of Ang(1-7). The addition of A779 significantly inhibited the improvement caused by Ang(1-7). CONCLUSION: Ang(1-7) can effectively reverseβ cell dedifferentiation through Wnt/β-catenin/FoxO1 pathway. It might be a new strategy for preventing and treating diabetes.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2023) studied Islet β cell dedifferentiation. Angiotensin (1-7) vs. High-glucose control, A779, CHIR99021 was evaluated on β-cell morphology, insulin secretory function, and expression of mature and progenitor cell markers. Angiotensin (1-7) effectively reversed high glucose-induced islet β cell dedifferentiation and improved insulin secretion through the Wnt/β-catenin/FoxO1 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: